1. Home
  2. BRW vs AGEN Comparison

BRW vs AGEN Comparison

Compare BRW & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRW
  • AGEN
  • Stock Information
  • Founded
  • BRW 1987
  • AGEN 1994
  • Country
  • BRW United States
  • AGEN United States
  • Employees
  • BRW N/A
  • AGEN N/A
  • Industry
  • BRW Trusts Except Educational Religious and Charitable
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BRW Finance
  • AGEN Health Care
  • Exchange
  • BRW Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • BRW 308.8M
  • AGEN 286.0M
  • IPO Year
  • BRW N/A
  • AGEN 2000
  • Fundamental
  • Price
  • BRW $7.26
  • AGEN $17.70
  • Analyst Decision
  • BRW
  • AGEN Strong Buy
  • Analyst Count
  • BRW 0
  • AGEN 2
  • Target Price
  • BRW N/A
  • AGEN $70.00
  • AVG Volume (30 Days)
  • BRW 222.1K
  • AGEN 572.2K
  • Earning Date
  • BRW 01-01-0001
  • AGEN 08-06-2024
  • Dividend Yield
  • BRW 15.59%
  • AGEN N/A
  • EPS Growth
  • BRW N/A
  • AGEN N/A
  • EPS
  • BRW N/A
  • AGEN N/A
  • Revenue
  • BRW N/A
  • AGEN $161,416,000.00
  • Revenue This Year
  • BRW N/A
  • AGEN $43.78
  • Revenue Next Year
  • BRW N/A
  • AGEN N/A
  • P/E Ratio
  • BRW N/A
  • AGEN N/A
  • Revenue Growth
  • BRW N/A
  • AGEN 69.94
  • 52 Week Low
  • BRW $7.15
  • AGEN $4.78
  • 52 Week High
  • BRW $8.30
  • AGEN $34.80
  • Technical
  • Relative Strength Index (RSI)
  • BRW 57.08
  • AGEN 66.14
  • Support Level
  • BRW $6.86
  • AGEN $14.77
  • Resistance Level
  • BRW $7.28
  • AGEN $18.74
  • Average True Range (ATR)
  • BRW 0.10
  • AGEN 1.40
  • MACD
  • BRW 0.03
  • AGEN 0.20
  • Stochastic Oscillator
  • BRW 76.32
  • AGEN 87.78

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund t is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: